Merger & Acquisitions

Bain Capital Acquires Mitsubishi Tanabe Pharma

by

Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued … Read more

LifeScience Weekly Digest: Key Industry Updates (13th – 17th January) 

by

JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more

Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle

by

Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more

Johnson & Johnson Steals the Spotlight at JPM Conference with $14.6B Intra-Cellular Therapies Acquisition

by

On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more

GSK snaps up IDRx for up to $1.15B

by

Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed … Read more

LifeScience Weekly Digest: Key Industry Updates (6th – 10th January) 

by

In early 2025, significant developments across the biopharmaceutical and medical device sectors shaped the healthcare landscape. Stryker’s $4.9 billion acquisition of Inari Medical, Transcarent’s $621 million deal for Accolade, and several FDA designations for investigational treatments, such as Johnson & Johnson’s nipocalimab, highlight industry advancements. Medicare’s rescinding of coverage for certain cancer genetic tests and … Read more

Transcarent paying $621M to acquire health benefits navigator Accolade 

by

Transcarent has announced plans to acquire Accolade for $621 million, marking a significant step toward its mission of delivering affordable and high-quality healthcare solutions. The acquisition will combine Transcarent’s innovative WayFinding and care solutions with Accolade’s personalized healthcare platform, creating a unified and comprehensive healthcare experience for users.  This collaboration aims to enhance accessibility to … Read more

OncoC4 merged with AcroImmune

by

OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more